OncoMatch/Clinical Trials/NCT04952272

Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors

Is NCT04952272 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CpG-ODN for lung cancer.

Phase 1RecruitingSecond Affiliated Hospital of Guangzhou Medical UniversityNCT04952272Data as of May 2026

Treatment: CpG-ODN — To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Hepatocellular Carcinoma

Tumor Agnostic

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify